LifeMD (NASDAQ: LFMD), a leading telehealth company, has announced robust first-quarter financial results for the period ending March 31, 2024. The company reported a significant increase in revenue and subscribers, particularly in its telehealth and weight management segments.
Total revenue reached $44.1 million, with cash adjusted EBITDA standing at $4.8 million, marking a 108% increase from the previous year. LifeMD also raised its 2024 revenue guidance to at least $205 million while maintaining its adjusted EBITDA forecast of $18 to $22 million.
Key Takeaways
- LifeMD added 20,000 new patient subscribers in Q1, bringing the total to over 235,000.
- The company's weight management business now has over 50,000 subscribers.
- Core telehealth business revenue surged by 53% year-over-year.
- LifeMD is launching new initiatives, including private and government insurance options and AI implementation.
- The company is preparing to introduce hormone replacement therapy and weight management programs under RexMD.
- LifeMD's consolidated gross margin reached a record 89.6%.
- The telehealth business is projected to become profitable by Q3 of 2024.
Company Outlook
- LifeMD expects to continue growing its GLP-1 weight management program and launch new offerings on RexMD.
- The company is focused on enhancing patient experience and investing in automation to support growth.
- LifeMD is planning to tap into the fee-for-service market for Medicare beneficiaries.
Bearish Highlights
- WorkSimpli active subscribers saw a contraction of 4% to over 166,000.
Bullish Highlights
- The GLP-1 weight management program has been a key growth driver, with strong cash flow from operations.
- LifeMD's telehealth subscriber base grew by 31%.
Misses
- Despite overall growth, WorkSimpli revenues saw a modest increase of 3%.
Q&A Highlights
- LifeMD discussed retention rates for weight management, with over 80% of patients remaining on treatment after 90 days despite a 15-20% drop-off.
- The company expressed enthusiasm for leveraging AI to enhance efficiency and scale operations.
- The upcoming RexMD weight management offering is targeted at men aged 40-50 with erectile dysfunction and chronic conditions, priced at around $300 per month.
- LifeMD's partnership with Medifast (NYSE:MED) is anticipated to contribute to second-half growth, though the majority of growth projections do not rely on this partnership.
LifeMD has demonstrated a strong start to 2024, with its telehealth services and weight management programs showing substantial growth. The company's strategic initiatives, including the expansion of insurance options and the introduction of AI, are set to further enhance its market position.
As LifeMD continues to focus on improving patient experience and technological capabilities, investors and stakeholders can look forward to the telehealth business's profitability in the upcoming quarters. With the next earnings call scheduled for August, LifeMD is poised to maintain its momentum and potentially exceed its financial targets for the year.
InvestingPro Insights
LifeMD (Ticker: LFMD) has shown impressive performance metrics that are worth noting. The company's gross profit margin for the last twelve months as of Q1 2024 stands at a remarkable 88.21%, highlighting its ability to efficiently manage production costs and maintain profitability in its operations. This metric is particularly relevant for investors looking to understand the company's financial health, especially in the competitive telehealth market.
InvestingPro Tips for LifeMD emphasize the company's high return over the last year, with a 629.59% price total return, which could be indicative of strong market confidence and growth potential. Additionally, the company has been trading near its 52-week high, with the price at 76.63% of this peak. This could suggest that investors are optimistic about the company's future prospects and its ability to sustain or improve its performance.
InvestingPro Data further reveals that LifeMD operates with a moderate level of debt, which is an important consideration for investors assessing the company's risk profile and long-term sustainability. The revenue growth for LifeMD has also been robust, with a 32.85% increase over the last twelve months as of Q1 2024, which is consistent with the company's reported financial results and its optimistic revenue guidance for the year.
For investors interested in gaining deeper insights into LifeMD and its market potential, there are additional InvestingPro Tips available on the platform. Discover more about LifeMD's financial health and strategic positioning by visiting https://www.investing.com/pro/LFMD. And for those looking to subscribe, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 10 more InvestingPro Tips listed in InvestingPro that could provide a more comprehensive understanding of LifeMD's investment potential.
Full transcript - LifeMD (LFMD) Q1 2024:
Operator: Good afternoon. Thank you for joining us today to discuss LifeMD's Results for the First Quarter ended March 31st, 2024. Joining on the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question-and-answer session. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected. These risks and uncertainties are described in the company's 10-K and 10-Q filings and within other filings that LifeMD may make with the SEC from time-to-time. Forward-looking statements made during this call are based on current information available to the company as of today, May 8th, 2024. The company assumes no obligation to update or revise any forward-looking statements after today's call except as required by law. Also, please note that management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release issued earlier today. Finally, I would like to remind everyone that today's call is being recorded and will be available for replay in the Investor Relations section of the company's website. Now, I'd like to turn the call over to LifeMD's CEO, Justin Schreiber. Please go ahead.
Justin Schreiber: Thank you and good afternoon everyone. After the market closed, we issued a press release announcing our first quarter financial results and posted an updated corporate presentation on our website at ir.lifemd.com. Last year's robust business momentum continued into 2024, producing strong first quarter performance across both our weight management and Rex businesses. During the quarter, we added 20,000 total patient subscribers, ending the quarter with over 235,000. As of the end of the first quarter we had over 42,000 weight management patient subscribers with performance in this area continuing to be well ahead of our expectations. As of today I am pleased to report we have over 50,000 weight management subscribers. Importantly, more than 80% of patients who start GLP-1 treatment, remain a patient after 90 days. And we are very pleased with these and subsequent first quarter retention figures. Our core telehealth business continues to outperform with revenue growing 53% versus the prior year. Continued outperformance in our GLP-1 business is the key driver behind the increase to 2024 revenue guidance we're announcing today. Our noncore subsidiary work simply started the year off with softer than expected results in January and February, before returning to growth in March and ending the quarter with a sequential increase of 8,000 subscribers. For the quarter, WorkSimpli revenue grew 3% versus the prior year but this business remains on track to achieve full year revenue and EBITDA goals consistent with our guidance. As we look ahead to the rest of 2024, we're focused on several key initiatives that we believe will catalyze significant growth in life of these market share and our top and bottom lines in 2024 and beyond. I'll speak more about each of these initiatives today which include one continued growth of our GLP-1 weight management program; two, new launches on RexMD. Three, the launch of private and government insurance options; and four, implementation of AI initiatives across our telehealth business. First, our weight management business continues to enjoy tremendous growth with demand for our services and products still consistently exceeding the supply of available appointments. As I mentioned we added a record 200,00 new patients in the first quarter with no signs of this trend slowing down. Unit economics remain tremendous with our day one return on ad spend continuing to exceed one times and our expected month 12 return on ad spend expected to be at least 2.5 times during the quarter. We also accelerated our rate of growth in new patient sign-ups from less than 200 per day to 400 plus new patients per day. Today, the single greatest limiting factor to our growth has been creating additional appointment capacity and our ability to scale our ratio of patients to providers. To accomplish this, we continue to invest in growing our clinical staff, but also and equally as important, we continue to invest in developing our platform's Automation and Technical Capabilities to create more, efficiencies for our affiliated providers and patient support teams, while enhancing the overall experience patients have on our platform. Additionally, we've recently begun to see significant up-ticks in the approval rates for GLP-1 payer coverage from the prior authorizations we file. Currently we see approval rates of 40% to 50% on Wegovy and Zepbound prior authorizations with co-pays averaging between $35 and $70. These figures are a big improvement from our approval rates earlier this year and they have contributed to our more recent refund rate declines, from nearly 33% to approximately 15% to 20% today. As announced in December, we signed a collaboration agreement with Medifast, one of the largest coach-guided diet and nutrition companies in the U.S., which included a $10 million equity investment and $10 million in collaboration fees for LifeMD. Medifast OPTAVIA Coaches are now able to work with LifeMD affiliated providers to provide patients with an integrated solution and holistic approach to Weight Management. Medifast will also be investing at least $25 million in consumer marketing to support growth of this program for the balance of 2024, which we expect to have a meaningful increase in the volumes of new patients acquired from this program. We are pleased with the collaboration to-date and look forward to providing more updates on this integrated offering as it is fully rolled out in the coming months. Moving to our second key initiative, we remain as excited as ever about our Rex&D brand which has consistently produced double-digit growth and strong profitability without the benefit of any new products. This quarter I am pleased to announce we expect to launch two new offerings into this brand. First, we plan to launch our Hormone Replacement Therapy offering led by Testosterone therapy. This offering not only presents a tremendous cross-sell opportunity for the existing Rex patient base, but also addresses a tremendous and underserved telemedicine market for LifeMD to tap into, within the men's health market that is highly synergistic to our existing Rex and GLP-1 Weight Management businesses. The current size of this market is estimated at $2 billion annually. And unlike many other categories LifeMD has successfully entered, we expect to be an early mover in this market from a Telehealth standpoint with a comprehensive and differentiated offering designed in conjunction with leading clinical experts in the field. We expect this offering to be a substantial contributor to the Company in the years to come. Additionally, later this month, we will we will also be launching our Weight Management Program under Rex&D has an Asynchronous offering. Similar to HRT, we expect this offering not only to have substantial cross-sell potential, but also to provide a valuable new avenue from which to market our industry-leading Weight Management program, as a bundled offering with clinical care. The fact is that in just four short years, Rex&D has grown to become one of the leading men's health brands in the US and has been trusted by over 500,000 men to-date. Rex&D patients typically have ample disposable income, are typically over the age of 40 and they know and trust Rex for the outstanding service and patient experience we provide. Our data suggests there is a substantial need for both HRT and Weight Management services among these patients. And we believe both of these new offerings have the ability to significantly accelerate the Rex&D business and in turn the LifeMD growth rate in the years to come. And under our third key 2024 initiative, we continue to make good progress preparing for the launch of our insurance program offerings. We are on track to launch our initial insurance visits on a limited state basis in the second quarter with the first state expected by late-May or early-June for our Virtual Primary Care offerings, including Weight Management. We have several payer contracts in place. We hired our initial Head of Revenue Cycle Management. And we are in the latter stages of finalizing our systems deployment for government provider enrollment, benefits verification and revenue cycle management. While we do not expect this launch to be material to 2024 results, we do believe insurance capabilities will be extremely valuable and differentiating in 2025 and beyond, while also driving further retention improvement. Additionally, we are extremely excited about launching government insurance capabilities by late 2024 or early 2025. The fact is this population is an entirely new audience for life and DI. Today there are over 65 million people enrolled in Medicare across the US with that number growing each year. In addition with the recent FDA approval of Wegovy for cardiac health estimates show that approximately four million people could receive coverage through Medicare for this drug. Because of this, we believe insurance and in particular government insurance plans represent a huge untapped market for LifeMD, which is why we've continued to build our compliance capabilities specifically geared towards supporting the needs of Medicare beneficiaries. By doing so, we also believe we are further differentiating ourselves into a telemedicine market leader that's capable of servicing the full range of patient populations and a significant number of health care needs. I'm pleased to announce that we have made meaningful progress in the implementation of AI across the organization. Since launching pilot AI features in early March, our patient care experts have achieved 60% greater response throughput for patient inquiries were over 48,000 responses have been sent to patients with support from our trained AI models. We've now also used AI classifiers to triage over 168, 000 patient messages across medical, administrative, shipping and technical categories for streamlined and improved patient care. We are just scratching the surface in this area and I'm excited to announce further improvements on our ability to scale, improve cost efficiency and deliver better cares in the quarters to come. In short, we are extremely excited about the potential for continued strong performance in 2024, while building new foundations for additional growth and differentiation in the years to come. And with that, I'll turn the call over to our CFO, Marc Benathen who will provide a summary of our financial results. Marc?
Marc Benathen: Thank you, Justin and good afternoon everyone. LifeMD had solid first quarter financial performance with total revenue growing to $44.1 million and cash adjusted EBITDA of $4.8 million, a 108% increase for this measure versus the prior year comparable period. Q1 revenue was up 33% versus the year ago period with telehealth revenues increasing 53% and WorkSimpli revenues increasing 3%. Adjusted EBITDA not including the increase in deferred revenue related to prepaid subscriptions primarily from weight management growth was approximately $500,000. WorkSimpli, which had soft January and February performance rebounded sharply in March and ended the quarter with a sequential increase in subscribers of 8,000 versus the prior quarter. Our GLP-1 weight management program continued to over-perform driving growth in telehealth and sizable benefits in cash flow from operations, which exceeded $5 million for the quarter and positive net cash flow as LifeMD's cash balance grew by $2 million during the quarter purely from strength of our D2C telehealth business. Telehealth subscriber growth remains strong with the number of active subscribers increasing 31% year-over-year to approximately 235,000 while WorkSimpli active subscribers contracted 4% to over 166,000. As I mentioned WorkSimpli subscribers did return to growth late in the quarter and ended the first quarter with an increase of 8000 subscribers compared to the fourth quarter of 2023. Importantly with this return to growth, we expect WorkSimpli to meet full year EBITDA expectations in the range of $17 million to $18 million and full year revenue expectations of $65 million. Consolidated gross margin for the first quarter was a record 89.6%, up 230 basis points versus the prior year period. Gross profit for the quarter totaled $39.5 million, an increase of 37% from the year ago period. Our GAAP net loss attributable to common stockholders for the first quarter totaled $7.5 million or a loss of $0.19 per share. This compares to a GAAP net loss attributable to common stockholders of $4.8 million or a loss of $0.15 per share in the first quarter of 2023. Adjusted EPS is a non-GAAP financial measure that excludes interest, taxes, non-cash expenses, dividends, stocks and insurance acceptance readiness, litigation expense, non-controlling interest, M&A, financing transaction costs and foreign currency translation. Reflecting those adjustments, adjusted diluted EPS for the first quarter was $0.01 compared with $0.06 in the year-ago period. Adjusted EBITDA, which is a non-GAAP financial measure that excludes the same items I noted for adjusted EPS, totaled $0.5 million in the first quarter of 2024. This compares with adjusted EBITDA of $2 million in the year-ago quarter. Importantly, though, when adjusting for the sizable increase in deferred revenue related to weight management, cash-adjusted EBITDA totaled $4.8 million, up from $2.3 million in the year-ago period, representing an increase of 108%. LifeMD generated $5.2 million of positive cash flow from operations during the first quarter of 2024 versus negative cash flow from operations of $2.6 million in the year-ago period. This is the fourth consecutive quarter of positive cash flow from operations, and the third quarter of positive net cash flow when factoring in cash flow from investing and financing activities. Cash balances totaled $35.1 million as of March 31st, 2024, an increase of $2 million versus the prior quarter, driven entirely by continued strength in cash flow generation from our telehealth operations. As Justin mentioned, we are raising our 2024 guidance for total revenue to be at least $205 million, up from at least $200 million previously, while reaffirming our adjusted EBITDA guidance to be between $18 and $22 million. This wraps up our financial results. I'd now like to turn the call back over to Justin.
Justin Schreiber: Thanks, Marc. As I've always said on these calls, I remain very optimistic and excited about the future of LifeMD. Our core businesses are growing, have dominant positions in very large markets, and have a clear and long-term growth trajectory. For the remainder of this year, we will focus on profitable growth of our telehealth business. This means relentlessly focusing on creating an amazing patient experience, investing in our differentiated telehealth services and products, and continuing to enhance and optimize our technology platform. Continued focus in these areas drives better patient outcomes, better retention, and better returns for shareholders. With that, I'd like to thank everyone for joining us today, and we'll now open the call to Q&A. Operator?
Operator: Thank you. [Operator Instructions] Your first question comes from David Larsen from BTIG. Please go ahead.
David Larsen: Hi, congratulations on the quarter. Can you maybe talk about your expectations for profitability of the healthcare business? Like, are you EBITDA break-even right now or not? What would you expect healthcare EBITDA to be in, say, 4Q of 2024, for example? And then, how should we be thinking about an EBITDA margin for healthcare as we head into 2025? Thank you.
Marc Benathen: Yeah, this is Marc, David. The telehealth EBITDA is slightly negative today. It is cash flow positive. The only reason it's negative is the deferred revenue from weight management. The EBITDA loss from telehealth this quarter was slightly below one million, so not very significant, actually. It's moving in the right direction. And again, with the sizable increase in deferred revenue of 4.3 million, if you add that to the about $1 million loss, telehealth business is actually three million dollars positive on a cash flow basis, so really moving in the right direction. We still expect the business, from a P&L standpoint, to turn profitable June, July of this year, which would mean the first quarter that you would see standalone profitability for telehealth would be the third quarter, and we expect a pretty steep slope up from that. In the fourth quarter, we do expect between $3 million to $5 million of EBITDA from the telehealth business by itself, and then next year, we do expect EBITDA to exceed $20 million on a full-year basis.
David Larsen: Okay. Fantastic. So $20 million of healthcare EBITDA for fiscal 2025, I guess is the guide. And then can you maybe just talk about what the drivers of that incremental profitability are? I mean, is it, is it, I mean, nothing simple, but is it as simple as gaining leverage with your, I think it's 30 providers that you have on your platform as you add more weight management members, you basically scale and they simply become more profitable. Is it that simple or are you sort of changing pricing or creating them?
Marc Benathe: No, no, no. I mean, we're not taking price increases. That's not our business. It's a few big factors. So firstly, we have about 70 providers today. But, where a lot of the profitability scale comes from is a few factors. One, continuing to leverage our marketing spend as a percent of sales. Right now, we're in a very heavy growth early phase of weight management. So you're not going to get much leverage at this point, but as we put on, we're over 50,000 patients at this point. As we put on more and more, a greater percentage of that revenue comes from rebilling of existing patients than comes from new patients. New patients have an acquisition marketing cost associated with it, which we are slightly in the red day one on a cash basis, obviously a GAAP basis. You look more indirect because you spread most of that over six months. Rebuild patients, almost all of that flows to the bottom line. You've essentially got your COGS and merchant fees. So, something like 70% to 80% of that flows to the bottom line. So that's the biggest lever is, obviously leveraging the marketing expense, retention of existing patients, which gets bigger and bigger as the base gets bigger in weight management. And then the other piece, as you mentioned, is just continuing to leverage our G&A, which, will move up as we get bigger, but it doesn't move up in lockstep with the rate of growth and revenue and leverage comes from that as well.
David Larsen: Okay. And just one more before I hop back in the queue. How many weight management members did you have at March 31, and then how many do you have right now?
Marc Benathe: Yeah, we have 42,000 at March 31, approximately, and we have slightly over 50,000 now.
David Larsen: Okay. Fantastic quarter. I'll hop back in the queue.
Marc Benathe: Thanks, David.
Operator: Your next question comes from Sarah James from Cantor. Please go ahead.
Sarah James: Thanks. So it's impressive growth to 70 physicians. Are you guys still looking at adding about four to five a month? And I think previously we talked about there being capacity for about 1,000 patients per physician. So does that mean that you guys have the capacity to go up to about 70,000 weight loss patients with your current staffing level?
Justin Schreiber: Hi, Sarah. This is Justin. So, we're continually adding providers to the platform. Four to five a month sounds like a fairly accurate number. It might be slightly more than that. It's a mix. You know, it's a mix of we are adding some part-time providers as well. And then as far as scale, I think we can -- I think we think the number is greater than 1,000 patients per provider. We probably think it's close to double that, especially if our tech is -- our tech is in place and kind of doing what we think it should be doing. So, but -- generally the goal -- our guide for this year, as we've talked about before, was based on that 350 new patient per day range. We do think we're going to end up coming in ahead of that, which is one of the reasons why we've increased the guidance a little bit today. And, if we were to scale to 1,000 patients a day, we would have to, we would have to probably double. We'd probably have to increase the physician group by at least 50%.
Sarah James: Thanks, Justin. And also, it's great coming with you guys getting set up in late 2024, early 2025 to launch the government insurance coinciding with the FDA approval of Wegovy for cardiac. How do you plan to tap into that market? So do you guys need to modify your marketing channels and strategy, and how are you thinking about leveraging your installed base with reps to tap into seniors?
Justin Schreiber: Well, we think there's a big opportunity there in the fee-for-service world with Medicare beneficiaries. I think they were initially our plan as to tackle this the same way in a very similar way to our current offerings, but allow people to use their Medicare or used their private insurance and then and then pay a concierge fee alongside of that for non-covered services.
Sarah James: Thank you.
Operator: Your next question comes from William Wood from B. Riley Securities. Please go ahead.
William Wood: Thank you, and congratulation on the very nice quarter, and thanks for taking my questions. So you recently passed the one-year mark when you launched your weight management business. Given that I've seen figures of upwards of like 60% of people that use GLP-1 drop off after the first 12 months, do you have any retention data possibly even for the six months that people, the first patients who started around this time last year, and then how many have stayed on for six months versus maybe even 12 months?
Marc Benathen: Yes. So from a retention standpoint, it's Marc, patients that go on therapy, as we've talked about before, we have that initial drop-off due to access issues, people not getting approved for coverage on the branded, not wanting to go on a compounded treatment, and not being able to afford the cash pay, which obviously many people can't afford. When we started the business in April of last year on the weight management side, for the first several months, that was about 33% of the cohort would drop off during that period. We're down to 15% to 20% dropping off now prior to approval rates have gotten better. Our communication, our diligence, and our processing has all gotten better. So that's been one win. If you go then to people that get on treatment, which typically you'll know in most cases within the first 30 days, sometimes it can extend longer because some prior authorizations go longer. The first 90 days that those people are on treatment, we see over 80%, it's actually about 80% or 83% remain on treatment after 90 days. So, really strong initial retention rates. The longest cohorts that we have today that are meaningful, I mean, the first couple of months is not really statistically significant, are about 10, 11 months old at this point. What we're seeing is we're seeing retention approaching about 50% of the total. But if you consider the fact that in those cohorts, so say you started with 100 people, 30 of them dropped off for access issues right away. The retention long-term of those people that are going on treatment still looks like it continues to be very good.
William Wood: Got it. Very helpful. Appreciate the color there. You also, I mean, you've noted just recently that to get up to 1,000 patients a day, you would need to increase providers by, like, 50%. Are you trying to bring in sort of the AI and more of the automation? Or how should we think about the continued scale-up and what it's really going to take with growing not only the top line but the bottom line?
Justin Schreiber: Yes. This is Justin. William, that's a good question. I mean, the AI is something we're really excited about, as we talked about during the call. We're seeing a lot of efficiencies now across the organization from rolling some of these things out. I mean, I think that over time it certainly will make a big impact on the clinical side, but I think near term the AI and a lot of the efficiencies that come from our technology platform are really kind of helping us to provide incredible care to more patients as we scale the business. They're reducing the costs associated with patient care, patient service, the call center, all of that stuff. So it certainly is going to play a role and help us to scale the business without expanding the overhead as much as we've had to kind of go from zero to 50,000.
William Wood: Got it. Appreciate that. And I'll jump back in queue. Thank you for taking our questions.
Operator: Your next question comes from Alex Fuhrman from Craig-Hallum. Please go ahead.
Alex Fuhrman: Hey, guys, thanks very much for taking my question. I wanted to ask, Justin, about the upcoming launch of a weight management offering under the RexMD brand on. Can you talk a little bit about, how you're going to go after that male consumer and just how that compares to your existing weight management business under the LifeMD brand, if you could maybe share with us, how much of that existing business it's male versus female?
Justin Schreiber: Yes. Hi, Alex. So – this Justin. So the initial focus of the RexMD weight management offering will be beyond like our existing database which is 150,000 to 200,000 active subscribers are 0.5 million subscriber, formerly active subscribers. And then we have a lot like millions of prospects in that database as well. So that's the initial focus -- those efforts -- there's clearly a lot of these people -- a lot of these men that are in the 40 -50 years old is kind of the target demo that have erectile dysfunction. We know at least 50% of them have multiple chronic conditions. Obesity is typically -- being overweight obese typically one of them. So, as far as, how we're going to target them, it's going to be very similar to the way that we've targeted men for erectile dysfunction and the other treatment offerings on RexMD. As far as how it's going to be structured, we have -- we plan to use the same technology platform that we use for our AD business, which is which is in a single platform. There's some same capabilities in certain states, where it's required, but we plan to use -- we use that same platform. It will be a bundle. We're planning to launch a bundled offering, which will include -- which will be -- basically a therapy a provider and the entire program similar to what we have on the weight management side, it's going to be priced somewhere around $300 a month, is the plan. And look, we just think that there's a big opportunity here within this demographic for a weight management offering and we're really excited about getting this thing launched. We're going to be launching in the next couple of weeks. So, it's a very near-term initiative for us.
Q – Alex Fuhrman: Great. That's really helpful Justin. Thanks. And then on the Medifast partnership, it sounds like they're going to be spending quite a bit of money marketing your joint offering in the third and the fourth quarter, can you give us a sense of how much of your expected growth in the back half of the year is expected to come from this RexMD light weight management offering as well as the Medifast partnership.
Justin Schreiber: The vast majority of the growth that we have in our guide for the year, really doesn't include Medifast and RexMD. So we think both of these things -- we think they're both going to be successful. And I think that's -- it's a lot of upside for the year. We're excited for both of them.
Q – Alex Fuhrman: That’s really helpful. Thank you, Justin.
Operator: [Operator Instructions] And there are no further questions, at this time. I will turn the call over to Justin Schreiber for closing remarks.
Justin Schreiber: Thanks everybody for your questions and for your interest in LifeMD. We look forward to speaking with you once again, when we report our second quarter results in August. Have a good evening.
Operator: Ladies and gentlemen, this concludes your conference call for today. You may now disconnect your lines. Thank you.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.